

SENATE BILL No. 704

December 3, 2013, Introduced by Senator HUNE and referred to the Committee on Health Policy.

A bill to amend 1978 PA 368, entitled "Public health code," by amending sections 16233, 16241, 17702, 17706, 17707, 17709, 17742, and 17748 (MCL 333.16233, 333.16241, 333.17702, 333.17706, 333.17707, 333.17709, 333.17742, and 333.17748), section 16233 as amended by 2010 PA 382, section 16241 as amended by 1993 PA 87, section 17702 as amended by 2012 PA 209, section 17706 as amended by 1986 PA 304, section 17707 as amended by 1990 PA 333, section 17709 as amended by 2006 PA 672, section 17742 as added by 1987 PA 250, and section 17748 as amended by 1988 PA 462, and by adding sections 17748a, 17748b, 17748c, and 17748d.

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

1 Sec. 16233. (1) The department may conduct an investigation
2 necessary to administer and enforce this article. Investigations
3 may include written, oral, or practical tests of a licensee's or
4 registrant's competency. The department may establish a special
5 paralegal unit to assist the department.

6 (2) The department may order an individual to cease and desist
7 from a violation of this article or article 7 or a rule promulgated
8 under this article or article 7.

9 (3) An individual ordered to cease and desist under subsection
10 (2) is entitled to a hearing before a hearings examiner if the
11 individual files a written request for a hearing within 30 days
12 after the effective date of the cease and desist order. The
13 department shall subsequently present the notice, if any, of the
14 individual's failure to respond to a complaint, or attend or be
15 represented at a hearing as described in sections 16231 and 16231a,
16 or the recommended findings of fact and conclusions of law to the
17 appropriate disciplinary subcommittee to determine whether the
18 order is to remain in effect or be dissolved.

19 (4) Upon a violation of a cease and desist order issued under
20 subsection (2), the department of attorney general may apply in the
21 circuit court to restrain and enjoin, temporarily or permanently,
22 an individual from further violating the cease and desist order.

23 (5) After consultation with the chair of the appropriate board
24 or task force or his or her designee, the department may summarily
25 suspend a license or registration if the public health, safety, or
26 welfare requires emergency action in accordance with section 92 of
27 the administrative procedures act of 1969, MCL 24.292. If a

1 licensee or registrant is convicted of a felony; a misdemeanor
2 punishable by imprisonment for a maximum term of 2 years; or a
3 misdemeanor involving the illegal delivery, possession, or use of a
4 controlled substance, the department shall find that the public
5 health, safety, or welfare requires emergency action and, in
6 accordance with section 92 of the administrative procedures act of
7 1969, MCL 24.292, shall summarily suspend the licensee's license or
8 the registrant's registration. If a licensee or registrant is
9 convicted of a misdemeanor involving the illegal delivery,
10 possession, or use of alcohol that adversely affects the licensee's
11 ability to practice in a safe and competent manner, the department
12 may find that the public health, safety, or welfare requires
13 emergency action and, in accordance with section 92 of the
14 administrative procedures act of 1969, MCL 24.292, may summarily
15 suspend the licensee's license or the registrant's registration.

16 **(6) THE DEPARTMENT MAY SUMMARILY SUSPEND A PHARMACY LICENSE IF**
17 **THE DEPARTMENT HAS RECEIVED A NOTICE FROM THE UNITED STATES FOOD**
18 **AND DRUG ADMINISTRATION OR THE CENTERS FOR DISEASE CONTROL AND**
19 **PREVENTION THAT THERE IS AN IMMINENT RISK TO THE PUBLIC HEALTH,**
20 **SAFETY, OR WELFARE AND EMERGENCY ACTION IN ACCORDANCE WITH SECTION**
21 **92 OF THE ADMINISTRATIVE PROCEDURES ACT OF 1969, MCL 24.292, IS**
22 **APPROPRIATE. A SUSPENSION UNDER THIS SUBSECTION REMAINS IN EFFECT**
23 **FOR THE DURATION OF THE EMERGENCY SITUATION THAT POSES A RISK TO**
24 **THE PUBLIC HEALTH, SAFETY, OR WELFARE. NOTWITHSTANDING ANY**
25 **PROVISION OF THIS ACT TO THE CONTRARY, THE DEPARTMENT IS NOT**
26 **REQUIRED TO CONDUCT AN INVESTIGATION OR CONSULT WITH THE BOARD OF**
27 **PHARMACY TO TAKE EMERGENCY ACTION UNDER THIS SUBSECTION.**

1 Sec. 16241. (1) After administrative disciplinary action is
2 final, the department ~~of commerce~~ shall publish a list of the names
3 and addresses of disciplined individuals. The department ~~of~~
4 ~~commerce~~ shall indicate on the list that a final administrative
5 disciplinary action is subject to judicial review. The department
6 ~~of commerce~~ shall report disciplinary action to the department of
7 ~~public~~ **COMMUNITY** health, the ~~commissioner of insurance,~~ **DEPARTMENT**
8 **OF INSURANCE AND FINANCIAL SERVICES**, the state and federal agencies
9 responsible for fiscal administration of federal health care
10 programs, and the appropriate professional association.

11 (2) Once each calendar year, the department ~~of commerce~~ shall
12 transmit to the library of Michigan sufficient copies of a
13 compilation of the lists required under subsection (1) for the
14 immediately preceding 3 calendar years. The library of Michigan
15 shall distribute the compilation to each depository library in ~~the~~
16 **THIS** state. The department ~~of commerce~~ also shall transmit the
17 compilation to each county clerk in ~~the~~ **THIS** state once each
18 calendar year.

19 (3) The department of ~~public~~ **COMMUNITY** health shall report the
20 disciplinary actions to appropriate licensed health facilities and
21 agencies. The ~~commissioner of insurance~~ **DEPARTMENT OF INSURANCE AND**
22 **FINANCIAL SERVICES** shall report the disciplinary actions received
23 from the department ~~of commerce~~ to insurance carriers providing
24 professional liability insurance.

25 (4) In case of a summary suspension of a license under section
26 16233(5), the department ~~of commerce~~ shall report the name and
27 address of the individual whose license has been suspended to the

1 department of ~~public~~ **COMMUNITY** health, the ~~commissioner of~~
2 ~~insurance,~~ **DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES**, the
3 state and federal agencies responsible for fiscal administration of
4 federal health care programs, and the appropriate professional
5 association. **IN CASE OF A SUMMARY SUSPENSION OF A LICENSE UNDER**
6 **SECTION 16233(6), THE DEPARTMENT SHALL REPORT THE NAME AND ADDRESS**
7 **OF THE PHARMACY LICENSE THAT HAS BEEN SUSPENDED TO THE DEPARTMENT**
8 **OF COMMUNITY HEALTH, THE DEPARTMENT OF INSURANCE AND FINANCIAL**
9 **SERVICES, THE STATE AND FEDERAL AGENCIES RESPONSIBLE FOR FISCAL**
10 **ADMINISTRATION OF FEDERAL HEALTH CARE PROGRAMS, AND THE APPROPRIATE**
11 **PROFESSIONAL ASSOCIATION.**

12 (5) A licensee or registrant whose license or registration is
13 revoked or suspended under this article shall give notice of the
14 revocation or suspension to each patient who contacts the licensee
15 or registrant for professional services during the term of the
16 revocation or suspension. The **LICENSEE OR REGISTRANT MAY GIVE THE**
17 notice required under this subsection ~~may be given orally and shall~~
18 ~~be given~~ **GIVE THE NOTICE REQUIRED UNDER THIS SUBSECTION** at the time
19 of contact.

20 (6) A licensee or registrant whose license or registration is
21 revoked or is suspended for more than 60 days under this article
22 shall notify in writing each patient or client to whom the licensee
23 or registrant rendered professional services in the licensee's or
24 registrant's private practice during the 120 days immediately
25 preceding the date of the final order imposing the revocation or
26 suspension and to each individual who is already scheduled for
27 professional services during the first 120 days after the date of

1 the final order imposing the revocation or suspension. The notice
2 ~~shall~~**MUST** be on a form provided by the licensee's or registrant's
3 board or task force and ~~shall~~ state, at a minimum, the name,
4 address, and license or registration number of the licensee or
5 registrant, the fact that his or her license or registration has
6 been revoked or suspended, the effective date of the revocation or
7 suspension, and the term of the revocation or suspension. Each
8 board or task force shall develop a notice form that meets at least
9 the minimum requirements of this subsection. The licensee or
10 registrant shall send the notice to each patient or client to whom
11 the licensee or registrant rendered professional services in the
12 licensee's or registrant's private practice during the 120 days
13 immediately preceding the date of the final order imposing the
14 revocation or suspension within 30 days after the date of the final
15 order imposing the revocation or suspension and shall
16 simultaneously transmit a copy of the notice to the department. The
17 licensee or registrant orally shall notify each individual who
18 contacts the licensee or registrant for professional services
19 during the first 120 days after the date of the final order
20 imposing the revocation or suspension. The licensee or registrant
21 shall also provide a copy of the notice within 10 days after the
22 date of the final order imposing the revocation or suspension to
23 his or her employer, if any, and to each hospital, if any, in which
24 the licensee or registrant is admitted to practice.

25 (7) A licensee or registrant who is reprimanded, fined, placed
26 on probation, or ordered to pay restitution under this article or
27 an applicant whose application for licensure or registration is

1 denied under this article shall notify his or her employer, if any,
2 and each hospital, if any, in which he or she is admitted to
3 practice, in the same manner as provided for notice of revocation
4 or suspension to an employer or hospital under subsection (6),
5 within 10 days after the date of the final order imposing the
6 sanction.

7 (8) The department ~~of commerce~~ annually shall report to the
8 legislature and to each board and task force on disciplinary
9 actions taken under this article and article 7. The ~~report~~
10 **DEPARTMENT** shall ~~contain,~~ **INCLUDE**, at a minimum, all of the
11 following information **IN THE REPORT REQUIRED UNDER THIS SUBSECTION:**

12 (a) Investigations conducted, complaints issued, and
13 settlements reached by the department, ~~of commerce,~~ separated out
14 by type of complaint and health profession.

15 (b) Investigations and complaints closed or dismissed.

16 (c) Actions taken by each disciplinary subcommittee, separated
17 out by type of complaint, health profession, and final order
18 issued.

19 (d) Recommendations by boards and task forces.

20 (e) The number of extensions and delays granted by the
21 department that were in excess of the time limits required under
22 this article for each phase of the disciplinary process, and the
23 types of cases for which the extensions and delays were granted.

24 ~~— (9) Within 2 years after the effective date of the amendatory~~
25 ~~act that added this subsection, the department of commerce shall~~
26 ~~submit a public report to the legislature on the effectiveness of~~
27 ~~the amendatory act that added this subsection. The report shall~~

1 ~~include a review and evaluation of the disciplinary process and the~~
2 ~~reporting requirements of this article and article 17 and~~
3 ~~recommended administrative or statutory changes, if any.~~

4 Sec. 17702. (1) "Agent" means an individual designated by a
5 prescriber to act on behalf of or at the discretion of that
6 prescriber as provided in section 17744.

7 (2) "Brand name" means the registered trademark name given to
8 a drug product by its manufacturer.

9 (3) EXCEPT AS OTHERWISE PROVIDED IN SUBSECTION (4),
10 "COMPOUNDING" MEANS THE PREPARATION, MIXING, ASSEMBLING, PACKAGING,
11 AND LABELING OF A DRUG OR DEVICE BY A PHARMACIST UNDER THE
12 FOLLOWING CIRCUMSTANCES:

13 (A) UPON THE RECEIPT OF A PRESCRIPTION FOR A SPECIFIC PATIENT.

14 (B) UPON THE RECEIPT OF A PRESCRIBER'S MEDICAL ORDER FOR USE
15 IN THE TREATMENT OF PATIENTS WITHIN THE COURSE OF THE PRESCRIBER'S
16 PROFESSIONAL PRACTICE.

17 (C) IN ANTICIPATION OF THE RECEIPT OF A PRESCRIPTION OR
18 MEDICAL ORDER BASED ON ROUTINE, REGULARLY OBSERVED PRESCRIPTION OR
19 MEDICAL ORDER PATTERNS.

20 (D) FOR THE PURPOSE OF OR INCIDENTAL TO RESEARCH, TEACHING, OR
21 CHEMICAL ANALYSIS AND NOT FOR THE PURPOSE OF SALE OR DISPENSING.

22 (4) "COMPOUNDING" DOES NOT INCLUDE ANY OF THE FOLLOWING:

23 (A) THE COMPOUNDING OF A DRUG PRODUCT THAT IS ESSENTIALLY A
24 COPY OF A COMMERCIALY AVAILABLE PRODUCT.

25 (B) THE RECONSTITUTION, MIXING, OR OTHER SIMILAR ACT THAT IS
26 PERFORMED PURSUANT TO THE DIRECTIONS CONTAINED IN APPROVED LABELING
27 PROVIDED BY THE MANUFACTURER OF A COMMERCIALY AVAILABLE PRODUCT.

1 (5) "COMPOUNDING PHARMACY" MEANS A PHARMACY LICENSED UNDER
2 THIS PART THAT MEETS THE REQUIREMENTS OF THIS PART TO OFFER
3 COMPOUNDING SERVICES.

4 (6) ~~(3)~~-"Current selling price" means the retail price for a
5 prescription drug that is available for sale from a pharmacy.

6 Sec. 17706. (1) "Manufacturer" means a person ~~who~~ **THAT**
7 prepares, produces, derives, propagates, compounds, processes,
8 packages, or repackages a drug or device salable on prescription
9 only, or otherwise changes the container or the labeling of a drug
10 or device salable on prescription only, and ~~who~~ **THAT** supplies,
11 distributes, sells, offers for sale, barter, or otherwise disposes
12 of that drug or device and any other drug or device salable on
13 prescription only, to another person for resale, compounding, or
14 dispensing.

15 (2) "Official compendium" means the United States
16 pharmacopoeia and **THE** national formulary, **OR THE** homeopathic
17 pharmacopoeia of the United States, ~~or a supplement thereof~~
18 ~~existing on July 1, 1983.~~ **AS APPLICABLE. IF AN OFFICIAL COMPENDIUM**
19 **IS REVISED AFTER THE EFFECTIVE DATE OF THE AMENDATORY ACT THAT**
20 **ADDED THIS SENTENCE, THE DEPARTMENT SHALL OFFICIALLY TAKE NOTICE OF**
21 **THE REVISION. WITHIN 30 DAYS AFTER TAKING NOTICE OF THE REVISION,**
22 **THE DEPARTMENT, IN CONSULTATION WITH THE BOARD, SHALL DECIDE**
23 **WHETHER THE REVISION CONTINUES TO PROTECT THE PUBLIC HEALTH AS IT**
24 **RELATES TO THE MANNER THAT THE OFFICIAL COMPENDIUM IS USED IN THIS**
25 **ACT. IF THE DEPARTMENT, IN CONSULTATION WITH THE BOARD, DECIDES**
26 **THAT THE REVISION CONTINUES TO PROTECT THE PUBLIC HEALTH, THE**
27 **DEPARTMENT MAY ISSUE AN ORDER TO INCORPORATE THE REVISION BY**

1 REFERENCE. IF THE DEPARTMENT ISSUES AN ORDER UNDER THIS SUBSECTION
2 TO INCORPORATE THE REVISION BY REFERENCE, THE DEPARTMENT SHALL NOT
3 MAKE ANY CHANGES TO THE REVISION.

4 Sec. 17707. (1) "Personal charge" means the immediate physical
5 presence of a pharmacist or dispensing prescriber.

6 (2) "Pharmacist" means an individual licensed under this
7 article to engage in the practice of pharmacy.

8 (3) "PHARMACIST IN CHARGE" OR "PIC" MEANS THE PHARMACIST WHO
9 IS RESPONSIBLE FOR COMPLIANCE WITH THIS PART AND RULES PROMULGATED
10 UNDER THIS PART IN ALL ASPECTS OF THE PRACTICE OF PHARMACY
11 INCLUDING, BUT NOT LIMITED TO, THE FOLLOWING:

12 (A) THE DISPENSING OF DRUGS, DEVICES, AND OTHER MATERIALS AT A
13 PHARMACY.

14 (B) THE SAFE, ACCURATE, SECURE, AND CONFIDENTIAL HANDLING AND
15 STORAGE OF DRUGS, DEVICES, AND PROTECTED HEALTH INFORMATION. AS
16 USED IN THIS SUBDIVISION, "HANDLING" INCLUDES, BUT IS NOT LIMITED
17 TO, THE PREPARATION, COMPOUNDING, DISTRIBUTING, AND DISPENSING OF
18 DRUGS AND DEVICES.

19 (C) BEING IN FULL AND ACTUAL CHARGE OF PHARMACY PERSONNEL.

20 (4) ~~(3)~~ "Pharmacist intern" or "intern" means an individual
21 who satisfactorily completes the requirements set forth in rules
22 promulgated ~~by the board~~ UNDER THIS PART and is licensed by the
23 board for the purpose of obtaining instruction in the practice of
24 pharmacy from a preceptor approved by the board.

25 (5) ~~(4)~~ "Pharmacy" means a building or part of a building in
26 which the practice of pharmacy is conducted. FOR THE PURPOSE OF A
27 DUTY PLACED ON A PHARMACY UNDER THIS PART, "PHARMACY" MEANS THE

1 **OWNER OR OPERATOR OF THE PHARMACY OR, IF APPROPRIATE, THE**
2 **PHARMACIST IN CHARGE.**

3 (6) ~~(5)~~—"Practice of pharmacy" means a health service, the
4 clinical application of which includes the encouragement of safety
5 and efficacy in the prescribing, dispensing, administering, and use
6 of drugs and related articles for the prevention of illness, and
7 the maintenance and management of health. Professional functions
8 associated with the practice of pharmacy include:

9 (a) The interpretation and evaluation of the prescription.

10 (b) Drug product selection.

11 (c) The compounding, dispensing, safe storage, and
12 distribution of drugs and devices.

13 (d) The maintenance of legally required records.

14 (e) Advising the prescriber and the patient as required as to
15 contents, therapeutic action, utilization, and possible adverse
16 reactions or interactions of drugs.

17 Sec. 17709. (1) "Sign" means to affix one's signature manually
18 to a document or to use an electronic signature when transmitting a
19 prescription electronically.

20 (2) **"STERILE PHARMACEUTICAL" MEANS A DOSAGE FORM OF A DRUG**
21 **THAT IS FREE FROM LIVING MICROBES AND FREE FROM CHEMICAL OR**
22 **PHYSICAL CONTAMINATION. AS USED IN THIS SUBSECTION, "DOSAGE FORM"**
23 **INCLUDES, BUT IS NOT LIMITED TO, PARENTERAL, INJECTABLE, AND**
24 **OPHTHALMIC DOSAGE FORMS.**

25 (3) ~~(2)~~—"Substitute" means to dispense, without the
26 prescriber's authorization, a different drug in place of the drug
27 prescribed.

1 (4) "USP STANDARDS" MEANS THE PHARMACOPEIAL STANDARDS FOR DRUG
2 SUBSTANCES, DOSAGE FORMS, AND COMPOUNDED PREPARATIONS BASED ON
3 DESIGNATED LEVELS OF RISK AS PUBLISHED IN THE OFFICIAL COMPENDIUM.

4 (5) ~~(3)~~—"Wholesale distributor" means a person, other than a
5 manufacturer, who supplies, distributes, sells, offers for sale,
6 barter, or otherwise disposes of, to other persons for resale,
7 compounding, or dispensing, a drug or device salable on
8 prescription only that the distributor has not prepared, produced,
9 derived, propagated, compounded, processed, packaged, or
10 repackaged, or otherwise changed the container or the labeling
11 thereof. **OF THE DRUG OR DEVICE.**

12 Sec. 17742. (1) The board may require an applicant or the
13 holder of a pharmacy, manufacturer's, or wholesale distributor's
14 license to fully disclose the identity of each partner,
15 stockholder, officer, or member of the board of directors of the
16 pharmacy, manufacturer, or wholesale distributor, as applicable.

17 (2) As used in this section and ~~section~~ **SECTIONS 17748,**
18 **17748A, AND** 17768, "applicant" means a person applying for a
19 pharmacy, manufacturer's, or wholesale distributor's license under
20 this article. Applicant includes only 1 or more of the following:

21 (a) An individual, if the person applying is an individual.

22 (b) All partners, including limited partners, if the person
23 applying is a partnership.

24 (c) All stockholders, officers, and members of the board of
25 directors, if the person applying is a privately held corporation.

26 Sec. 17748. (1) ~~A~~ **TO DO BUSINESS IN THIS STATE, A** pharmacy,
27 manufacturer, or wholesale distributor, ~~of prescription drugs,~~

1 whether or not located in this state, ~~but doing business in this~~
2 ~~state, shall MUST~~ be licensed by the board in accordance with ~~UNDER~~
3 this part. Licenses ~~shall be renewed~~ **ARE RENEWABLE** biennially.

4 (2) A pharmacy ~~, manufacturer, or wholesale distributor~~ may
5 **SHALL** designate ~~an individual to be~~ **A PHARMACIST LICENSED IN THIS**
6 **STATE AS** the licensee ~~PHARMACIST IN CHARGE~~ for the pharmacy. ~~,~~
7 ~~manufacturer, or wholesale distributor and the licensee~~ **A**
8 **MANUFACTURER OR WHOLESALE DISTRIBUTOR SHALL DESIGNATE A PHARMACIST**
9 **LICENSED IN OR OUTSIDE OF THIS STATE AS THE PHARMACIST IN CHARGE**
10 **FOR THE MANUFACTURER OR WHOLESALE DISTRIBUTOR. THE INDIVIDUAL**
11 **DESIGNATED AS THE PIC UNDER THIS SUBSECTION** is responsible for **THE**
12 **PHARMACY'S, MANUFACTURER'S, OR WHOLESALE DISTRIBUTOR'S** compliance
13 with this part.

14 (3) **A PHARMACY, MANUFACTURER, OR WHOLESALE DISTRIBUTOR SHALL**
15 **REPORT TO THE DEPARTMENT A CHANGE IN OWNERSHIP, MANAGEMENT,**
16 **LOCATION, OR DESIGNATED PIC NOT LATER THAN 30 DAYS AFTER THE CHANGE**
17 **OCCURS.**

18 (4) **CONSISTENT WITH ACCEPTED STANDARDS OF PROFESSIONAL CONDUCT**
19 **AND PRACTICE AND IN COMPLIANCE WITH ALL APPLICABLE LAWS AND RULES,**
20 **A PIC SHALL DO ALL OF THE FOLLOWING:**

21 (A) **BE RESPONSIBLE FOR THE PURCHASING, STORAGE, COMPOUNDING,**
22 **REPACKAGING, DISPENSING, AND DISTRIBUTION OF ALL DRUGS AND DEVICES.**

23 (B) **ESTABLISH POLICIES AND PROCEDURES FOR THE EMPLOYEES OF THE**
24 **PHARMACY FOR THE PROCUREMENT, STORAGE, COMPOUNDING, AND DISPENSING**
25 **OF DRUGS AND THE COMMUNICATION OF INFORMATION TO THE PATIENT IN**
26 **RELATION TO DRUG THERAPY.**

27 (C) **SUPERVISE ALL EMPLOYEES PERFORMING TASKS LISTED IN**

1 SUBDIVISION (B) AND PROVIDE OVERSIGHT OF THE PHARMACY IF THE
2 PHARMACY IS ALSO LICENSED AS A MANUFACTURER.

3 (D) SUPERVISE A NONPROFESSIONAL EMPLOYEE OF THE PHARMACY IF
4 THE EMPLOYEE'S DUTIES ARE RELATED TO THE PROCUREMENT, SALE,
5 DISPENSING, OR STORAGE OF DRUGS.

6 (E) ESTABLISH AND SUPERVISE THE METHOD AND MANNER FOR THE
7 STORING AND SAFEKEEPING OF DRUGS.

8 (F) ESTABLISH AND SUPERVISE THE RECORDKEEPING SYSTEM FOR THE
9 PURCHASE, SALE, POSSESSION, STORAGE, SAFEKEEPING, AND RETURN OF
10 DRUGS.

11 (G) NOTIFY THE BOARD IMMEDIATELY UPON THE KNOWLEDGE THAT THE
12 SERVICES OF THE PHARMACIST IN CHARGE HAVE BEEN OR WILL BE
13 TERMINATED.

14 (H) ESTABLISH POLICIES AND PROCEDURES FOR INDIVIDUALS WITHIN
15 THE PHARMACY WHO ARE DELEGATED TASKS BY THE PIC.

16 (5) EXCEPT AS OTHERWISE PROVIDED IN THIS SUBSECTION, AN
17 APPLICANT FOR A NEW PHARMACY, MANUFACTURER, OR WHOLESALE
18 DISTRIBUTOR LICENSE UNDER THIS PART WHO IS NOT A HEALTH
19 PROFESSIONAL LICENSED OR OTHERWISE AUTHORIZED TO ENGAGE IN A HEALTH
20 PROFESSION UNDER THIS ARTICLE OR WHO IS A HEALTH PROFESSIONAL BUT
21 WAS LICENSED OR OTHERWISE AUTHORIZED TO ENGAGE IN HIS OR HER HEALTH
22 PROFESSION UNDER THIS ARTICLE BEFORE OCTOBER 1, 2008 SHALL SUBMIT
23 FINGERPRINTS IN THE SAME MANNER AS REQUIRED IN SECTION 16174 FOR
24 THE PURPOSE OF A CRIMINAL HISTORY CHECK. THE BOARD, DEPARTMENT, AND
25 DEPARTMENT OF STATE POLICE SHALL COMPLY WITH SECTION 16174 FOR THE
26 PURPOSE OF A CRIMINAL HISTORY CHECK ON AN APPLICANT DESCRIBED IN
27 THIS SUBSECTION. THIS SUBSECTION DOES NOT APPLY IF A CRIMINAL

1 HISTORY CHECK THAT MEETS THE REQUIREMENTS OF SECTION 16174 HAS BEEN
2 OBTAINED FOR THE APPLICANT WITHIN THE 2 YEARS PRECEDING THE DATE OF
3 THE APPLICATION. TO QUALIFY FOR THE EXCEPTION UNDER THIS
4 SUBSECTION, THE APPLICANT SHALL SUBMIT PROOF OF THE PREVIOUS
5 CRIMINAL HISTORY CHECK WITH HIS OR HER APPLICATION FOR A NEW
6 PHARMACY, MANUFACTURER, OR WHOLESALE DISTRIBUTOR LICENSE UNDER THIS
7 PART. IF THE DEPARTMENT OR BOARD DETERMINES THAT THE CRIMINAL
8 HISTORY CHECK DOES NOT MEET THE REQUIREMENTS OF SECTION 16174 OR
9 WAS NOT OBTAINED WITHIN THE TIME PERIOD PRESCRIBED, THE APPLICANT
10 SHALL COMPLY WITH THIS SUBSECTION.

11 SEC. 17748A. (1) BEGINNING ON THE EFFECTIVE DATE OF THIS
12 SECTION, AN APPLICANT FOR A NEW PHARMACY LICENSE FOR A PHARMACY
13 THAT WILL PROVIDE COMPOUNDING SERVICES SHALL SUBMIT VERIFICATION OF
14 CURRENT ACCREDITATION THROUGH A NATIONAL ACCREDITING ORGANIZATION
15 APPROVED BY THE BOARD OR VERIFY THE PHARMACY IS IN THE
16 ACCREDITATION PROCESS. THE DEPARTMENT SHALL NOT ISSUE A LICENSE TO
17 A PHARMACY DESCRIBED IN THIS SUBSECTION THAT IS NOT ACCREDITED
18 UNLESS THE APPLICANT DEMONSTRATES COMPLIANCE WITH USP STANDARDS.

19 (2) BY 1 YEAR AFTER THE EFFECTIVE DATE OF THIS SECTION, A
20 PHARMACY THAT IS LICENSED ON THE EFFECTIVE DATE OF THIS SECTION AND
21 THAT PROVIDES COMPOUNDING SERVICES SHALL BE ACCREDITED BY A
22 NATIONAL ACCREDITING ORGANIZATION APPROVED BY THE BOARD OR BE IN
23 COMPLIANCE WITH USP STANDARDS IN A MANNER DETERMINED BY THE BOARD.

24 (3) NOTWITHSTANDING ANY PROVISION OF PART 161 TO THE CONTRARY,
25 A PHARMACY THAT PROVIDES COMPOUNDING SERVICES SHALL SUBMIT WITH A
26 LICENSE RENEWAL APPLICATION VERIFICATION OF CURRENT ACCREDITATION
27 OR COMPLIANCE WITH USP STANDARDS, AS APPLICABLE.

1 (4) A PHARMACY THAT PROVIDES COMPOUNDING SERVICES SHALL COMPLY
2 WITH REQUIREMENTS OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION
3 APPLICABLE TO THE COMPOUNDING SERVICES.

4 (5) A PHARMACY SHALL NOTIFY THE DEPARTMENT OF A COMPLAINT
5 REGARDING COMPOUNDING ACTIVITIES FILED BY ANOTHER STATE IN WHICH
6 THE PHARMACY IS LICENSED FOR VIOLATIONS OF THAT STATE'S PHARMACY
7 LAWS, AN INVESTIGATION BY FEDERAL AUTHORITIES REGARDING VIOLATIONS
8 OF FEDERAL LAW, OR AN INVESTIGATION BY ANY AGENCY INTO VIOLATIONS
9 OF ACCREDITATION STANDARDS WITHIN 30 DAYS OF KNOWLEDGE OF THE
10 COMPLAINT OR INVESTIGATION.

11 (6) A PHARMACIST SHALL MAINTAIN A RECORD OF A COMPOUNDED
12 STERILE PHARMACEUTICAL IN THE SAME MANNER AND FOR THE SAME
13 RETENTION PERIOD AS PRESCRIBED IN RULES FOR OTHER PRESCRIPTION
14 RECORDS. THE PHARMACIST SHALL INCLUDE, BUT IS NOT LIMITED TO
15 INCLUDING, ALL OF THE FOLLOWING INFORMATION IN THE RECORD REQUIRED
16 UNDER THIS SUBSECTION:

17 (A) THE NAME, STRENGTH, QUANTITY, AND DOSAGE FORM OF THE
18 COMPOUNDED PHARMACEUTICAL.

19 (B) THE FORMULA TO COMPOUND THAT INCLUDES MIXING INSTRUCTIONS,
20 ALL INGREDIENTS AND THEIR QUANTITIES, AND ANY ADDITIONAL
21 INFORMATION NEEDED TO PREPARE THE COMPOUNDED PHARMACEUTICAL.

22 (C) THE PRESCRIPTION NUMBER OR ASSIGNED INTERNAL
23 IDENTIFICATION NUMBER.

24 (D) THE DATE OF PREPARATION.

25 (E) THE MANUFACTURER AND LOT NUMBER OF EACH INGREDIENT.

26 (F) THE EXPIRATION OR BEYOND-USE DATE.

27 (G) THE NAME OF THE PERSON WHO PREPARED THE COMPOUNDED

1 PHARMACEUTICAL.

2 (H) THE NAME OF THE PHARMACIST WHO APPROVED THE COMPOUNDED
3 PHARMACEUTICAL.

4 (7) A PHARMACIST SHALL NOT OFFER EXCESS COMPOUNDED
5 PHARMACEUTICALS TO OTHER PHARMACIES FOR RESALE. A COMPOUNDING
6 PHARMACY SHALL NOT DISTRIBUTE SAMPLES OF A COMPOUNDED
7 PHARMACEUTICAL TO A HEALTH PROFESSIONAL.

8 (8) A COMPOUNDING PHARMACY MAY ADVERTISE OR OTHERWISE PROMOTE
9 THE FACT THAT THEY PROVIDE COMPOUNDING SERVICES.

10 (9) BASED ON THE EXISTENCE OF A HEALTH PROFESSIONAL/PATIENT
11 RELATIONSHIP AND THE PRESENTATION OF A VALID PRESCRIPTION, OR IN
12 ANTICIPATION OF THE RECEIPT OF A PRESCRIPTION BASED ON ROUTINE,
13 REGULARLY OBSERVED PRESCRIPTION PATTERNS, A PHARMACIST MAY COMPOUND
14 FOR A PATIENT A NONSTERILE OR STERILE PHARMACEUTICAL THAT IS NOT
15 COMMERCIALY AVAILABLE IN THE MARKETPLACE.

16 (10) NOTWITHSTANDING ANY PROVISION OF THIS ACT TO THE
17 CONTRARY, A PERSON SHALL NOT COMPOUND AND MANUFACTURE DRUG PRODUCTS
18 OR ALLOW THE COMPOUNDING AND MANUFACTURING OF DRUG PRODUCTS AT THE
19 SAME LOCATION.

20 (11) THE DEPARTMENT, IN CONSULTATION WITH THE BOARD, MAY
21 PROMULGATE RULES REGARDING CONDITIONS, GOOD COMPOUNDING PRACTICES,
22 AND FACILITIES FOR THE COMPOUNDING OF NONSTERILE AND STERILE
23 PHARMACEUTICALS.

24 SEC. 17748B. (1) EXCEPT AS OTHERWISE PROVIDED IN THIS
25 SUBSECTION, A PHARMACIST OR PHARMACY SHALL NOT COMPOUND NONSTERILE
26 OR STERILE PHARMACEUTICALS FOR A PRESCRIBER OR HEALTH FACILITY OR
27 AGENCY LICENSED UNDER ARTICLE 17 TO ADMINISTER TO THE PRESCRIBER'S,

1 FACILITY'S, OR AGENCY'S PATIENTS WITHOUT A PRESCRIPTION. UPON
2 APPLICATION BY A PHARMACIST OR COMPOUNDING PHARMACY, THE DEPARTMENT
3 MAY AUTHORIZE THE PHARMACIST OR COMPOUNDING PHARMACY TO COMPOUND
4 NONSTERILE OR STERILE PHARMACEUTICALS FOR A PRESCRIBER OR HEALTH
5 FACILITY OR AGENCY LICENSED UNDER ARTICLE 17 TO ADMINISTER TO THE
6 PRESCRIBER'S, FACILITY'S, OR AGENCY'S PATIENTS IN LIMITED
7 QUANTITIES WITHOUT A PRESCRIPTION. THIS SUBSECTION DOES NOT APPLY
8 TO THE COMPOUNDING OF TOPICAL NONSTERILE PHARMACEUTICALS. THE
9 DEPARTMENT SHALL PRESCRIBE THE FORM OF THE APPLICATION FOR USE
10 UNDER THIS SUBSECTION, WHICH APPLICATION MUST INCLUDE AT LEAST ALL
11 OF THE FOLLOWING INFORMATION:

12 (A) THE NAME AND LICENSE NUMBER OF THE PHARMACIST OR PHARMACY
13 REQUESTING AUTHORIZATION TO COMPOUND UNDER THIS SUBSECTION.

14 (B) THE NAME OF THE SPECIFIC PRESCRIBER OR HEALTH FACILITY OR
15 AGENCY THAT IS REQUESTING COMPOUNDED PHARMACEUTICALS AND AN
16 AFFIDAVIT FROM THE PRESCRIBER OR DESIGNATED AGENT OF THE HEALTH
17 FACILITY OR AGENCY ATTESTING TO THE NEED AND THAT THE COMPOUNDED
18 PHARMACEUTICALS ARE ONLY FOR PATIENTS LOCATED IN THIS STATE OR IN
19 STATES IMMEDIATELY ADJACENT TO THIS STATE.

20 (C) THE PHARMACEUTICALS TO BE COMPOUNDED AND THE REASON FOR
21 THE NEED TO COMPOUND THE PHARMACEUTICALS.

22 (D) THE ANTICIPATED QUANTITIES OF PHARMACEUTICALS TO BE
23 COMPOUNDED EACH MONTH AND THE FREQUENCY OF THE NEED TO COMPOUND
24 BEFORE RECEIPT OF A PRESCRIPTION OR DOCUMENTATION SUPPORTING THE
25 ANTICIPATED QUANTITIES.

26 (E) THE CONDITIONS OF OPERATION INCLUDING PRACTICES CONSISTENT
27 WITH USP STANDARDS AND REQUIREMENTS FOR THIRD-PARTY TESTING.

1 (2) A PHARMACIST OR COMPOUNDING PHARMACY THAT IS AUTHORIZED TO
2 COMPOUND NONSTERILE OR STERILE PHARMACEUTICALS FOR A PRESCRIBER OR
3 HEALTH FACILITY OR AGENCY UNDER SUBSECTION (1) SHALL DO ALL OF THE
4 FOLLOWING:

5 (A) MAINTAIN COMPLETE AND ACCURATE RECORDS ON A MONTHLY BASIS
6 OF REQUESTS FROM AND PHARMACEUTICALS COMPOUNDED FOR EACH PRESCRIBER
7 OR HEALTH FACILITY OR AGENCY.

8 (B) PROVIDE THE INFORMATION DESCRIBED IN SUBDIVISION (A) TO
9 THE DEPARTMENT AS SPECIFIED IN RULES OR UPON REQUEST.

10 (3) THE AUTHORIZATION GRANTED UNDER SUBSECTION (1) IS FOR A 1-
11 YEAR PERIOD AND IS SUBJECT TO RENEWAL BY THE DEPARTMENT. THE
12 DEPARTMENT MAY, WITHOUT PRIOR NOTICE TO THE PHARMACIST OR PHARMACY,
13 PHYSICALLY INSPECT THE FACILITY WHERE THE COMPOUNDING OF NONSTERILE
14 OR STERILE PHARMACEUTICALS OCCURS.

15 (4) THE DEPARTMENT SHALL NOT AUTHORIZE A PHARMACIST OR
16 COMPOUNDING PHARMACY TO COMPOUND NONSTERILE OR STERILE
17 PHARMACEUTICALS WITHOUT A PRESCRIPTION IF THE PHARMACIST OR
18 PHARMACY IS UNDER INVESTIGATION, IS IN THE PROCESS OF BEING
19 DISCIPLINED, OR IS IN A DISCIPLINARY STATUS.

20 (5) EXCEPT AS OTHERWISE PROVIDED IN THIS SUBSECTION, THE
21 DEPARTMENT MAY IMMEDIATELY REVOKE THE AUTHORIZATION GRANTED UNDER
22 SUBSECTION (1) IF THERE IS A CONFIRMED DEVIATION OR VIOLATION OF
23 THE COMPOUNDING PROCESS OR IF AN ADVERSE EVENT ASSOCIATED WITH A
24 COMPOUNDED NONSTERILE OR STERILE PHARMACEUTICAL IS DETECTED. IF THE
25 HEALTH, SAFETY, AND WELFARE OF THE PUBLIC ARE NOT IN IMMEDIATE
26 JEOPARDY, THE DEPARTMENT SHALL PROVIDE AT LEAST 30 DAYS' NOTICE OF
27 THE REVOCATION OF AUTHORIZATION UNDER THIS SUBSECTION.

1 (6) A PHARMACY OR PHARMACIST AUTHORIZED TO COMPOUND
2 PHARMACEUTICALS UNDER THIS SECTION THAT BECOMES AWARE OF AN ADVERSE
3 EVENT ASSOCIATED WITH A COMPOUNDED PHARMACEUTICAL SHALL REPORT THE
4 ADVERSE EVENT TO THE DEPARTMENT NOT LATER THAN 10 CALENDAR DAYS
5 AFTER BECOMING AWARE OF THE ADVERSE EVENT.

6 (7) THE DEPARTMENT SHALL POST AND MAINTAIN A LIST OF
7 PHARMACIES AND PHARMACISTS WHO ARE AUTHORIZED TO COMPOUND
8 PHARMACEUTICALS UNDER THIS SECTION ON ITS INTERNET WEBSITE.

9 (8) A PRESCRIBER OR HEALTH FACILITY OR AGENCY THAT OBTAINS
10 COMPOUNDED PHARMACEUTICALS UNDER THIS SECTION SHALL NOT REDISPENSE
11 OR SELL THE COMPOUNDED PHARMACEUTICAL TO A PATIENT, A PRESCRIBER,
12 OR HEALTH FACILITY OR AGENCY.

13 SEC. 17748C. A PHARMACIST SHALL NOT COMPOUND A PHARMACEUTICAL
14 THAT IS COMMERCIALY AVAILABLE UNLESS ALL OF THE FOLLOWING
15 REQUIREMENTS ARE MET:

16 (A) THE COMMERCIALY AVAILABLE PHARMACEUTICAL IS MODIFIED TO
17 PRODUCE A SIGNIFICANT DIFFERENCE, IN THE PROFESSIONAL JUDGMENT OF
18 THE PRESCRIBER, BETWEEN THE COMPOUNDED PHARMACEUTICAL FOR THE
19 PATIENT AND THE COMPARABLE COMMERCIALY AVAILABLE PHARMACEUTICAL.

20 (B) THE COMMERCIALY AVAILABLE PHARMACEUTICAL IS NOT AVAILABLE
21 FROM NORMAL DISTRIBUTION CHANNELS IN A TIMELY MANNER TO MEET THE
22 PATIENT'S NEEDS AND THE DISPENSING OF THE COMPOUNDED PHARMACEUTICAL
23 HAS BEEN APPROVED BY THE PRESCRIBER AND THE PATIENT. A PHARMACIST
24 WHO COMPOUNDS A COMMERCIALY AVAILABLE PHARMACEUTICAL AS PROVIDED
25 IN THIS SUBDIVISION SHALL MAINTAIN DOCUMENTATION OF THE REASON FOR
26 THE COMPOUNDING.

27 SEC. 17748D. (1) EXCEPT AS OTHERWISE PROVIDED IN THIS SECTION,

1 A PERSON THAT VIOLATES SECTION 17748A OR 17748B IS GUILTY OF A
2 MISDEMEANOR.

3 (2) EXCEPT AS OTHERWISE PROVIDED IN THIS SECTION, A PERSON
4 THAT KNOWINGLY OR WILLFULLY VIOLATES SECTION 17748A OR 17748B OR A
5 PERSON THAT FALSIFIES PRESCRIPTIONS IN ORDER TO COMPOUND A
6 PHARMACEUTICAL IN BULK IS GUILTY OF A FELONY PUNISHABLE BY
7 IMPRISONMENT FOR NOT MORE THAN 2 YEARS OR A FINE OF NOT MORE THAN
8 \$1,000.00, OR BOTH.

9 (3) EXCEPT AS OTHERWISE PROVIDED IN THIS SECTION, A PERSON
10 THAT KNOWINGLY OR WILLFULLY VIOLATES SECTION 17748A OR 17748B OR A
11 PERSON THAT FALSIFIES PRESCRIPTIONS IN ORDER TO COMPOUND A
12 PHARMACEUTICAL IN BULK, WHICH ACTIVITY RESULTS IN PERSONAL INJURY,
13 IS GUILTY OF A FELONY PUNISHABLE BY IMPRISONMENT FOR NOT MORE THAN
14 4 YEARS OR A FINE OF NOT MORE THAN \$4,000.00, OR BOTH.

15 (4) A PERSON THAT KNOWINGLY OR WILLFULLY VIOLATES SECTION
16 17748A OR 17748B OR A PERSON THAT FALSIFIES PRESCRIPTIONS IN ORDER
17 TO COMPOUND A PHARMACEUTICAL IN BULK, WHICH ACTIVITY RESULTS IN
18 SERIOUS IMPAIRMENT OF A BODY FUNCTION, IS GUILTY OF A FELONY
19 PUNISHABLE BY IMPRISONMENT FOR NOT MORE THAN 5 YEARS OR A FINE OF
20 NOT MORE THAN \$5,000.00, OR BOTH. AS USED IN THIS SUBSECTION,
21 "SERIOUS IMPAIRMENT OF A BODY FUNCTION" MEANS THAT TERM AS DEFINED
22 IN SECTION 58C OF THE MICHIGAN VEHICLE CODE, 1949 PA 300, MCL
23 257.58C.

24 (5) A PERSON THAT KNOWINGLY OR WILLFULLY VIOLATES SECTION
25 17748A OR 17748B OR A PERSON THAT FALSIFIES PRESCRIPTIONS IN ORDER
26 TO COMPOUND A PHARMACEUTICAL IN BULK, WHICH ACTIVITY RESULTS IN
27 DEATH, IS GUILTY OF A FELONY PUNISHABLE BY IMPRISONMENT FOR NOT

1 MORE THAN 15 YEARS OR A FINE OF NOT MORE THAN \$20,000,00, OR BOTH.

2 (6) THE STATE ATTORNEY GENERAL OR LOCAL PROSECUTOR IS
3 AUTHORIZED TO ADVANCE AND PROSECUTE CRIMINAL CHARGES DESCRIBED IN
4 THIS SECTION.